Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia

BACKGROUND: Thrombopoietin-receptor agonists eltrombopag (EPAG) and romiplostim (ROMI) are treatment options for adults with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids or immunoglobulins. METHODS: A cost-consequence model was developed to evaluate...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clinicoecon Outcomes Res
Egile Nagusiak: Tremblay, Gabriel, Dolph, Mike, Bhor, Menaka, Said, Qayyim, Elliott, Brian, Briggs, Andrew
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6219311/
https://ncbi.nlm.nih.gov/pubmed/30464563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S177324
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak